Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)

Hiroshi Watanabe/DigitalVision via Getty Images Insmed's Phase 3 Success: Brensocatib's Promising Future In my previous article on Insmed (NASDAQ:INSM), I highlighted robust revenue growth from their lead drug, Arikayce, for the treatment of mycobacterium avium complex [MAC] lung infections, but also noted their high R&D costs for difficult-to-treat conditions with high attrition rates, such as bronchiectasis. I recommended a "hold" based on the combination of financial and operational risk and reward. Toda ...